Class / Patent application number | Description | Number of patent applications / Date published |
514648000 | Two aryl rings or aryl ring systems bonded directly to the same acyclic carbon | 44 |
20080207765 | METHOD FOR INHIBITING NEURONAL CELL DEATH INDUCED BY OXIDATIVE GLUTAMATE TOXICITY - A neuronal cell death induced by an oxidative glutamate toxicity is substantially inhibited by administrating to an mammal an effective amount of a phenylenediamine derivative compound of formula (I), wherein R is phenyl or butyl. | 08-28-2008 |
20080249183 | Treatment of androgen-deprivation induced osteoporosis - This invention provides a method of treating androgen-deprivation induced osteoporosis, bone fractures or loss of bone mineral density (BMD) in a male human subject suffering from prostate cancer, wherein the subject has a precipitous decline in androgen levels, by administering a pharmaceutical composition comprising Toremifene or its analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, or any combination thereof, to the subject, wherein the method increases bone density without increasing androgen and specifically testosterone levels in the subject. | 10-09-2008 |
20080255243 | Stat3 as a theranostic indicator - This invention relates, e.g., to a method for predicting the response of a subject having estrogen-receptor-positive breast cancer to an inhibitor of the estrogen signaling pathway (e.g. tamoxifen), comprising measuring in a cancer sample from the subject the level of phosphorylation, compared to a baseline value, of one or more of the following members of an interconnected intracellular signaling pathway: (a) 4EBP1, and/or (b) p70S6, and/or (c) STAT3, and/or (d) FAK, wherein a significantly elevated level of phosphorylation of 4EBP1, and/or p70S6 and/or STAT3, and/or a significantly decreased level of phosphorylation of FAK, compared to the baseline value, indicates that the subject is likely to be a non-responder to the inhibitor and/or has a poor prognosis. Additional members of the intracellular signaling pathway whose phosphorylation can be measured are also described. Also described is a method for treating breast cancer in a subject in need thereof, wherein the subject exhibits an elevated level of phosphorylation of these markers, comprising administering to the subject an effective amount of one or more inhibitors of members of the interconnected intracellular signaling pathway. | 10-16-2008 |
20080287549 | METHODS AND MATERIALS FOR CONTROLLING RODENT POPULATIONS - The present invention relates to the use of compositions comprising clomiphene isomers for controlling rodent populations. The clomiphene isomers lower testosterone and/or suppress appetite in the rodent population. | 11-20-2008 |
20080293823 | Methods and Compositions For Treating Sleep-Related Breathing Disorders - Provided herein are methods of treating a sleep-related breathing disorder, such as obstructive sleep apnea, comprising the administration of O-desmethylvenlafaxine or duloxetine. | 11-27-2008 |
20090018207 | SUBSTITUTED PHENETHYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY - Chemical syntheses and medical uses of novel inhibitors of the uptake of monoamine neurotransmitters and pharmaceutically acceptable salts and prodrugs thereof, for the treatment and/or management of psychotropic disorders, anxiety disorder, generalized anxiety disorder, depression, post-traumatic stress disorder, obsessive-compulsive disorder, panic disorder, hot flashes, senile dementia, migraine, hepatopulmonary syndrome, chronic pain, nociceptive pain, neuropathic pain, painful diabetic retinopathy, bipolar depression, obstructive sleep apnea, psychiatric disorders, premenstrual dysphoric disorder, social phobia, social anxiety disorder, urinary incontinence, anorexia, bulimia nervosa, obesity, ischemia, head injury, calcium overload in brain cells, drug dependence, and/or premature ejaculation are described. | 01-15-2009 |
20090062398 | DEUTERIUM-ENRICHED TOLTERODINE - The present application describes deuterium-enriched tolterodine, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 03-05-2009 |
20090082467 | TREATMENT OF MIGRAINE HEADACHES USING ANTIESTROGENS - A method of preventing the occurrence of migraine headaches in a patient who is a previous sufferer of migraine headaches comprises administering an effective amount therefor of an antiestrogen to the patient for a period of time and sufficiently far in advance of the occurrence of a migraine headache to prevent the development of the prodromal phase of the migraine headache. | 03-26-2009 |
20090105348 | TREATMENT OF MIGRAINE HEADACHES USING ANTIESTROGENS - A method of preventing the occurrence of migraine headaches in a patient who is a previous sufferer of migraine headaches, especially accompanied by prodrome and/or aura, comprises administering an effective amount therefor of an antiestrogen to the patient for a period of time and sufficiently far in advance of the occurrence of a migraine headache to prevent the development of the prodromal phase and/or aura phase of the migraine headache. | 04-23-2009 |
20090186944 | PREVENTION AND TREATMENT OF BREAST CANCER WITH 4-HYDROXY TAMOXIFEN - Pharmaceutical compositions of 4-hydroxy tamoxifen, particularly compositions suitable for percutaneous administration, are useful in methods for treating and preventing breast cancer. When percutaneously administered to a patient's breasts, 4-hydroxy tamoxifen concentrates locally, and exerts an anti-estrogenic effect. In patients with breast cancer, this effect reduces tumor tissue proliferation. In patients at risk for developing breast cancer, the anti-estrogenic effect prevents breast tumor formation. | 07-23-2009 |
20090192228 | Controlled-Release Tolterodine Compositions and Methods - Controlled-release tolterodine compositions, including controlled-release particles, pellets, granules, and spheres, comprising an inert core, a first layer disposed on the inert core, and a second layer disposed on the first layer are described. Methods for preparing such compositions and methods of treating a variety of disorders are also disclosed. | 07-30-2009 |
20090203796 | TREATMENT AND PREVENTION OF BENIGN BREAST DISEASE WITH 4-HYDROXY TAMOXIFEN - The present invention provides methods for treating and preventing benign breast disease by administering 4-hydroxy tamoxifen to a patient. When percutaneously administered to a patient's breasts, 4-hydroxy tamoxifen concentrates locally, and exerts an anti-estrogenic effect. In patients with benign breast disease, this effect induces disease regression. In patients at risk for developing breast cancer, the anti-estrogenic effect prevents formation of benign breast conditions that can lead to cancer. | 08-13-2009 |
20090234019 | T Type Calcium Channel Inhibitors - The present invention provides novel T type calcium channel inhibitors of formula (I), the use thereof in the treatment of a disease or condition in a mammal associated with influx of extracellular calcium via T type calcium channels, | 09-17-2009 |
20090281194 | Combinations for treating HIV-associated pain - The present invention relates to novel combinations suitable for the treatment or amelioration of pain of various genesis or aetiology, which comprise, as active ingredients, at least one cannabinoid receptor binding compound, in particular a cannabinoid receptor binding naphthalene derivative, and at least one opioid, to their preparation, to their use as medicaments and to medicaments comprising them. | 11-12-2009 |
20100010096 | Methadone chiral isolate as an improved pharmaceutical - Methadone is a frequently employed agent for the treatment of drug addiction and the treatment of pain. Methadone prolongs the cardiac action potential, which on the surface electrocardiogram is represented by QT prolongation. This QT prolongation is known to increase the risk for the development of cardiac arrhythmias, especially the form of ventricular tachycardia known as Torsade de Pointes. For this reason, the FDA has inserted a “black box” warning for potential life threatening arrhythmias. The invention described in this application is the surprising finding that the R-isomer of methadone causes less inhibition of the potassium channel, IKr and thus would have less of a chance of causing life threatening arrhythmias. What is claimed is a method of chirally separating methadone with one isomer having less QT prolongation and more analgesic action that would make a superior pharmacologic agent than the racemate R,S methadone. | 01-14-2010 |
20100130617 | ETHANOLAMINE MODULATORS OF NMDA RECEPTOR AND MUSCARINIC ACETYLCHOLINE RECEPTOR - The present invention relates to new ethanolamine modulators of NMDA receptors and/or muscarinic acetylcholine receptors, pharmaceutical compositions thereof, and methods of use thereof. | 05-27-2010 |
20100197800 | Treatment and/or Prevention of Presbycusis by Modulation of Metabotropic Glutamate Receptor 7 - The invention relates to the treatment and/or prevention of age-related hearing loss (presbycusis) with a modulator of a metabotropic glutamate receptor 7 (mGluR7). | 08-05-2010 |
20100234473 | PROCESS FOR PREPARATION OF 3-(2-HYDROXY-5-SUBSTITUTED PHENYL)-N-ALKYL-3-PHENYLPROPYLAMINES - A new process for preparation of 3-(2-hydroxy-5-substituted phenyl)-N,alkyl-3-phenylpropylamines from cinnamyl chloride via N-alky-3-phenylprop-2-en-1-amine has been developed. | 09-16-2010 |
20100317740 | Method for Predicting Response to Tamoxifen - This invention relates, e.g., to a method for predicting the response of a subject having, or at risk of developing, breast cancer to Tamoxifen therapy. The method comprises measuring the amount of phosphorylation at residues S70 of Bcl-2, Y992 of EGFR, and/or Y527 of Src in a suitable sample from the subject, wherein a statistically significantly elevated level of phosphorylation at one or more of the three residues compared to a baseline value indicates that the subject is likely to be responsive to Tamoxifen therapy. | 12-16-2010 |
20110034562 | PSYCHO-PHARMACEUTICALS - The invention provides a selective Sigma 1 or Dopamine D3 receptor agonist or a 5HT2c receptor ligand for use in the treatment of symptoms of anxiety and/or depression associated with an affective disorder and/or symptoms associated with cognitive impairment disorder. Particularly useful are diphenhydramine derivatives of Formula (I) and particularly (2-[(4-butylsulfanylphenyl)-phenyl-methyl]sulfanyl-N,N-dimethyl-ethanamin) (Captodiamine). | 02-10-2011 |
20110136913 | ASSESSING AND TREATING BREAST CANCER PATIENTS - This document provides methods and materials related to assessing and treating breast cancer patients. For example, methods and materials that involve assessing a breast cancer patient to determine whether the patient has (1) cancer cells that over express HER-2 polypeptides or comprise a HER-2 amplification and (2) at least an intermediate CYP2D6 metabolizer status are provided. | 06-09-2011 |
20110269841 | THIN FILM WITH METHADONE ACTIVE INGREDIENT - An orally dissolvable thin film strip for the administration of the pharmaceutical active Methadone is formed by mixing a wet slurry of a water-soluble polymer, a polar solvent, Methadone HCl, and optional additives. The slurry is then cast onto a substrate by slot die or knife-over-roll and is dried in an oven at a temperature that exceeds the boiling point of the solvent. The resulting dried thin film is cut into individual doses designed to administer 5 mg, 10 mg, or 40 mg of Methadone HCl. | 11-03-2011 |
20110281952 | DEUTERIUM-ENRICHED TOLTERODINE - The present application describes deuterium-enriched tolterodine, pharmaceutically acceptable salt forms thereof, and methods of treating using the same. | 11-17-2011 |
20120122992 | SMALL MOLECULE INHIBITORS OF Dusp6 AND USES THEREFOR - Compounds that stimulate fibroblast growth factor production, and thus cell growth are provided. Also provided are compositions comprising the compounds and methods of using the compounds. The compounds can be used to treat wounds, to expand cell populations, such as hematopoietic cells, or to grow tissue in vitro, among other uses. | 05-17-2012 |
20120157542 | METHOD TO ASSESS PROGNOSIS AND TO PREDICT THERAPEUTIC SUCCESS IN CANCER BY DETERMINING HORMONE RECEPTOR EXPRESSION LEVELS - The present invention is related to a method of classifying a sample of a patient who suffers from or being at risk of developing cancer, said method comprising the steps of determining in said sample from said patient, on a non protein basis, the expression level of at least one gene encoding for a hormone receptor selected from the group comprising estrogen receptor, progesterone receptor and/or androgen receptor in said sample; comparing the one or more expression level(s) determined with one or more expression level(s) of one or more reference genes, and classifying the sample of said patient from the outcome of the comparison into one of at least two classifications. | 06-21-2012 |
20120178821 | POLYMORPHIC FORM OF TOREMIFENE CITRATE AND PROCESS FOR ITS PREPARATION - The present invention provides a polymorphic form of toremifene citrate and processes for its preparation. It also relates to an improved process for the preparation of the Z isomer of the toremifene base, free of E isomer, and its pharmaceutically acceptable salts. | 07-12-2012 |
20120245231 | Weight based dosing of an oral solution having diphenhydramine, or pharmaceutically acceptable salts thereof, as an active ingredient - The present invention is directed toward a method of administering an oral solution containing one or more active ingredients, preferably formulations for non-prescription medicines, vital fluids, and/or nutritional supplements, optimally dosed based upon a patient's weight. The method includes providing an oral solution having an effective amount of one or more active ingredients; determining the weight of the individual, preferably to an individual less than 12 years old; and administrating an appropriate amount of the oral solution in a single dose dispensing unit in accordance with the weight determination of the individual, whereby the total amount of active ingredient administered corresponds to an effective amount of the active ingredient based on the individual's weight. | 09-27-2012 |
20120270947 | Short Telomere Length on Chromosome 9P is Strongly Associated with Breast Cancer Risk - Disclosed are compositions and methods related to assessing the risk of cancer, such as breast cancer, through analyzing the length of telomeres, such as chromosome 9p telomere, such as the short arm of the 9p telomere. If the 9p arm is shorter than normal, the risk of cancer is increased. | 10-25-2012 |
20120309839 | DOSING REGIMES FOR TRANS-CLOMIPHENE - The present invention relates to the use of compositions comprising trans-clomiphene for treating men with hypogonadism. The invention is also directed to methods for treating males with hypogonadism and disorders related thereto, including reduction of muscle mass. limitation of body performance capacity, reduction of bone density, reduction of libido, reduction of potency, reduction of benign prostatic hyperplasia and infertility. | 12-06-2012 |
20130046026 | COMPOSITION WITH IMPROVED SKIN PENETRATION FOR TRANSDERMAL DELIVERY OF TOLTERODINE - Disclosed is a composition for transdermal administration containing tolterodine. The composition comprises lidocaine or a pharmaceutically acceptable salt thereof to achieve enhanced skin penetration. The composition enhances the skin penetration of tolterodine. Therefore, a successful commercial application of a tolterodine-containing transdermal preparation based on the composition can be expected. | 02-21-2013 |
20130085183 | AROMATIC BUTAN-2-OL COMPOUNDS AND PREPARATION AND USES THEREOF - Aromatic butan-2-ol compounds, preparation methods for making the compounds, and uses of the compounds are provided. Specifically, the compound of Formula I, or an optical isomer, racemate, diastereomer, pharmaceutically acceptable salt, or solvate thereof, is provided, where each of the substituents is defined. In addition, a pharmaceutical composition containing the compound, and the use of the compound in manufacture of a medicament for the treatment and/or prophylaxis of a disease or disorder caused by | 04-04-2013 |
20130217779 | METHADONE CHIRAL ISOLATE AS AN IMPROVED PHARMACEUTICAL - The present invention relates to a method for treating drug addiction or neuropathic pain in a patient known to be vulnerable to life threatening cardiac arrhythmias (e.g., abnormally prolonged QT intervals, potassium chanelopathies, hypokalemia, or a combination thereof) by administering the R isolate of methadone to the patient. | 08-22-2013 |
20130296438 | METHODS AND COMPOSITIONS FOR USE WITH K-RAS MEDIATED DISORDERS - Methods and compositions that can be used to identify and characterize inhibitors of K-ras localization to the plasma membrane and in doing so inhibit the signal transduction of K-ras. Such compositions can be used to treat K-ras mediated disorders, such as cancer. | 11-07-2013 |
20130296439 | STABILIZED TOLTERODINE TARTRATE FORMULATIONS - A method of making a pharmaceutical composition containing tolterodine L-tartrate stabilized against degradation with an acid. Acid-stabilized tolterodine L-tartrate may be used as an active ingredient in various types of immediate release and controlled release dosage forms, including tablets, capsules, and beads. | 11-07-2013 |
20140018435 | Transdermal Delivery of Therapeutic Agents Using Poly (Amidoamine) Dendrimers - The invention provides for compositions for transdermal delivery of a therapeutic agent associated with a surface modified poly(amidoamine) PAMAM dendrimer, wherein the surface modified dendrimer increased skin penetration of the therapeutic agent. The invention particularly provides for compositions and methods for transdermal delivery of anticancer and chemo-preventive agents. | 01-16-2014 |
20140179796 | MARKERS FOR DCIS RECURRENCE: COORDINATE PTEN/RB LOSS - The technology described herein relates to compositions, kits, assays, systems and methods relating to breast cancer and the treatment thereof. | 06-26-2014 |
20140200277 | METHODS OF FACILITATING NEURAL CELL SURVIVAL USING NON-PEPTIDE AND PEPTIDE BDNF NEUROTROPHIN MIMETICS - Methods and compounds for treating neurological and other disorders are provided. Included is the administering to a subject in need thereof an effective amount of a compound having binding and/or modulation specificity for a TrkB receptor molecule. | 07-17-2014 |
20140350117 | Topical Scar Treatment Composition and Method of Using Same - The present disclosure describes a topical scar treatment composition that may include tamoxifen citrate in a concentration of about 0.01% by weight to about 1% by weight, with about 0.1% by weight being preferred, and an anhydrous silicone base for enhancing skin permeation and scar removing effects, in a concentration of about 10% by weight to about 100% by weight, with about 100% being preferred being preferred. The small concentration of tamoxifen citrate may prevent dangerous side effects and may be successful in treating abnormal scars such as keloids and hypertrophic scars. | 11-27-2014 |
20150111970 | GENETIC MARKERS AND DIAGNOSTIC METHODS FOR RESISTANCE OF BREAST CANCER TO HORMONAL THERAPIES - This application provides a method to identify genetic markers associated with increased sensitivity or resistance to hormonal therapies using an outlier analysis. More specifically, this application discloses that amplifications on chromosomes 8 and 17 are associated with increased proliferation and poor outcome in ER-positive breast cancer, and amplicons 17q21.33-q25.1, 8p11.2 and 8q24.3 may be responsible for higher proliferation and poor outcome in the setting of antiestrogen, in particular Tamoxifen, treatment clinically observed in a subset of ER-positive, HER2-negative breast cancers. The invention also provides use of the identified genetic markers in the development of targeted treatments for antiestrogen-resistant ER-positive breast cancers as well as in improving current methods of drug response prediction. | 04-23-2015 |
20150126611 | 3,3-DIPHENYL-N-(1-PHENYLETHYL) PROPAN-1-AMINE: AS A NEW SELECTIVE LIGAND OF THE SIGMA-1 RECEPTORS, WITH ANTI-APOPTOTIC (CYTOPROTECTIVE) PROPERTIES AND PROTOTYPICAL ANTICANCER ACTIVITY - 3,3-diphenyl-N-(1-phenylethyl) propan-1-amine (fendiline): as a new selective ligand of the sigma-1 receptors, with anti-apoptotic (cytoprotective) properties and prototypical anticancer activity. This invention concerns the prototypical profile of selective sigma-1 ligand and the putative therapeutical properties of the compound 3,3-diphenyl-N-(1-phenylethyl) propan-1-amine (DPPA) and its pharmaceutically acceptable salts, with cytoprotective activity, more specifically for neurons against the neurodegenerative diseases (e.g. Alzheimer's disease, Huntington's disease, Parkinson's disease) via their anti-apoptotic properties induced by their selective sigma-1 agonism. Concerning the cancer cells, DPPA exhibited pro-apoptotic properties associated with neuroprotective activity originating a prototypical anticancer profile consisting in synergistical association with the clinically used anticancer drugs with its analgesic and neuroprotective activities antagonizing the neuropathic pain induced by the later. | 05-07-2015 |
20150329913 | Identification of a 5-Gene Expression Signature Predicting Clinical Outcome of Patients with Brain Tumors - High-grade gliomas are the most common brain tumors in humans and are essentially incurable. The defining hallmark of these high-grade gliomas is the presence within the tumor mass of highly tumorigenic cellular subpopulations that fuel tumor aggressiveness. Identification of the molecular mechanisms remains elusive. Therefore, there is a need for diagnostic markers to accurately determine the type of glioma and appropriate treatment. Gene delivery vehicles are provided that comprise an oncogene, IRES-Cre-ER cassette and a gene encoding an oligonucleotide that inhibits p53 including shp53. Methods are also provided for determining a diagnosis and for treatment of non-aggressive and aggressive gliomas. | 11-19-2015 |
20160046559 | NON-PEPTIDE BDNF NEUROTROPHIN MIMETICS - Methods and compounds for treating neurological and other disorders are provided. Included is the administering to a subject in need thereof an effective amount of a compound having binding and/or modulation specificity for a TrkB receptor molecule, optionally optionally in combination with a TrkA and/or TrkC receptor molecule. | 02-18-2016 |
20160113889 | Small Molecule Inhibitors of Dusp6 and Uses Therefor - Compounds that stimulate fibroblast growth factor production, and thus cell growth are provided. Also provided are compositions comprising the compounds and methods of using the compounds. The compounds can be used to treat wounds, to expand cell populations, such as hematopoietic cells, or to grow tissue in vitro, among other uses. | 04-28-2016 |
20160128953 | TRANS-CLOMIPHENE AND ITS ANALOGUES AS AGENTS THAT INCREASE BONE MINERAL DENSITY - The present invention relates to the administration of compositions comprising trans-clomiphene or an analogue or salt thereof, for inhibiting bone resorption and bone turnover in a subject. The invention is also directed to methods for increasing bone mineral density in a subject and preventing or treating a bone related disorder in a subject comprising administering to the subject an effective amount of trans-clomiphene or an analogue or salt thereof. | 05-12-2016 |